Medicare payments to hospitals treating cancer patients with Novartis AG’ Kymriah (tisagenlecleucel) and Gilead Sciences Inc.’s Yescarta (axicabtagene ciloleucel) will not increase significantly in 2020 despite requests from manufacturers, providers and other advocates, which argue that access to the treatment is currently challenged by inadequate reimbursement.
In its 2020 Medicare payment update final rule for hospital inpatient services and technologies, released 2 July, the Centers...







